Lung diseases are the leading cause of mortality worldwide. The currently available
therapies are not sufficient, leading to the urgent need for new therapies with sustained anti …

Pulmonary delivery of messenger RNA (mRNA) has considerable potential as therapy or
vaccine for a range of lung diseases. Inhaled dry powder formulation of mRNA is particularly …

The treatment and management of COPD by inhalation to the lungs has emerged as an
attractive alternative route to oral dosing due to higher concentrations of the drug being …

Systemic administration of antifungal agents for the treatment of pulmonary aspergillosis is
limited by the poor lung deposition and severe adverse effects. In contrast, pulmonary …

Conclusion In summary, dry powder formulations are a promising dosage form to locally
deliver target-specific siRNA enabling the therapy of several diseases such as asthma …

Pulmonary delivery of small interfering RNAs (siRNAs) has shown promising results for the
treatment of lung diseases with gene disorders. The aim of this work was to evaluate the …

Ciprofloxacin (CIP) apparent permeability and absorption rate across the pulmonary
epithelium can be controlled by its complexation with copper (II) ion. The aim of the current …

The development of small interfering RNA (siRNA) formulation for pulmonary delivery is a
key to the clinical translation of siRNA therapeutics for the treatment of respiratory diseases …

In order to evaluate the in vivo effect of inhaled formulations, it is a gold standard to create a
lung metastasis model by intravenously injecting cancer cells into an animal. Because the …

Formulation of inhalable delivery systems containing tuberculosis (TB) antigens to target the
site of infection (lungs) have been considered for the development of subunit vaccines. Inert …